经臀磁共振成像引导与经直肠超声引导前列腺穿刺活检结果与前列腺切除标本高度一致
该研究评估了经臀磁共振成像(MRI)引导前列腺穿刺活检的效用。在1年内共评估960例穿刺系列,包括301例MRI引导和659例经直肠超声(TRUS)引导活检。MRI引导活检的阳性率和高分级癌比例显著高于TRUS引导活检,且癌组织量明显更多。活检Gleason分级与前列腺切除标本比较显示两种引导方式一致性很高且几乎相同,但MRI引导后行手术的临床无意义癌比例显著降低。
要点
- MRI引导活检阳性率65.4%(301例中)显著高于TRUS引导57.2%(659例中)(P=0.016)。
- MRI引导活检中Gleason 3+3=6癌占16.8%(197例中),显著低于TRUS引导的36.1%(377例中)(P<0.001)。
- MRI引导后前列腺切除标本中Gleason 3+3=6癌比例为2.5%,显著低于TRUS引导后的11.2%(P=0.021)。
核心结论
- 经臀MRI引导前列腺穿刺活检对高危癌有高检出率,同时检测到临床无意义癌的风险似乎降低。
- 这本身可能导致不必要的前列腺切除术减少。
- 由于MRI引导活检可获得过量组织用于分析,分子检测更好适用可能进一步避免过度治疗,尤其是在潜在低危癌患者中。
研究设计与样本
- 研究评估了1年内采集的960例穿刺系列,包括301例MRI引导和659例TRUS引导活检。
- 对80例MRI引导和170例非MRI引导活检患者进行了活检Gleason分级与前列腺切除标本的比较。
主要发现
- MRI引导活检中65.4%(301例中)含癌,TRUS引导活检中57.2%(659例中)含癌(P=0.016)。
- Gleason 3+3=6疾病在MRI引导活检中占16.8%(197例中),在TRUS引导活检中占36.1%(377例中)(P<0.001)。
- 所有癌中,MRI引导活检的平均癌表面积为64.8±51.6 mm²,非MRI引导活检为23.0±31.4 mm²(P<0.001)。
- Gleason 3+3=6癌中,MRI引导活检癌组织量为20.9±27.9 mm²,非MRI引导为5.1±10.2 mm²(P<0.001);Gleason 3+4=7癌中分别为59.7±38.0 mm²和17.7±18.4 mm²(P<0.001)。
- 两种方法在低风险活检结果患者中均有约10%存在未检测到的高危癌;前列腺切除标本中Gleason 3+3=6癌比例在TRUS活检后队列为11.2%,在MRI活检后队列仅为2.5%(P=0.021)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the utility of our transgluteal magnetic resonance imaging (MRI)-guided prostate biopsy approach. PATIENTS AND METHODS: A total of 960 biopsy series, taken within the period of 1 year, were evaluated, including 301 MRI-guided and 659 transrectal ultrasonography (TRUS)-guided biopsies. RESULTS: The positivity rate and proportion of high grade cancers were significantly higher in MRI-guided than in TRUS-guided biopsies. Of 301 MRI-guided biopsies, 65.4% contained cancer while 57.2% of 659 TRUS biopsies contained cancer (P = 0.016). Gleason grade 3 + 3 = 6 disease was observed in 16.8% of 197 MRI-guided and in 36.1% of 377 TRUS-guided biopsies (P < 0.001). There was also a markedly higher quantity of cancer tissue in MRI-guided biopsies. In all cancers, the mean cancer surface area was 64.8 ± 51.6 mm2 in MRI-guided biopsies as compared with 23.0 ± 31.4 mm2 in non-MRI-guided biopsies (P < 0.001). With respect to the tissue quantity, superiority of MRI-guided biopsy was highest in Gleason grade 3 + 3 = 6 cancers (20.9 ± 27.9 vs 5.1 ± 10.2 mm2 ; P < 0.001) and in Gleason grade 3 + 4 = 7 cancers (59.7 ± 38.0 vs 17.7 ± 18.4 mm2 ; P < 0.001). Comparison of biopsy Gleason grades with findings in prostatectomy specimens was possible in 80 patients with MRI-guided and in 170 patients with non-MRI-guided biopsies. This comparison showed a very high but almost identical concordance of TRUS- and MRI-guided biopsies with the prostatectomy specimen findings. With both approaches, undetected high-risk cancers were present in ~10% of patients with low-risk biopsy results. A significant difference was observed, however, in the proportion of patients who had clinically insignificant cancers and who underwent surgery. The proportion of patients with Gleason grade 3 + 3 = 6 carcinoma in their prostatectomy specimen was 11.2% in the post-TRUS biopsy cohort, but only 2.5% in the post-MRI biopsy cohort (P = 0.021). CONCLUSION: MRI-guided transgluteal prostate biopsy has a high detection rate for high-risk carcinomas, while the risk of detecting clinically insignificant carcinomas appears to be reduced. This may by itself lead to a reduction of unnecessary prostatectomies. Overtreatment may be further avoided by better applicability of molecular testing to MRI-guided biopsies because of the excessive amount of tissue available for analysis, especially in patients with potential low-risk carcinomas.
引用
- Steurer S, Rico SD, Simon R, et al. High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens. BJU Int. 2017. PMID: 28295933. doi:10.1111/bju.13840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。